Future directions for health technology assessment in Australia provides a unified industry viewpoint on how the reform of the HTA system could substantially improve and enhance access to genomic technology for health consumers.

InGeNA's view is there would be more equitable access to genomic testing if health technology assessment (HTA) processes were improved.

Genomics is complex and evolving rapidly. Therefore, successful integration into clinical practice will require effective collaboration across the genomics value chain, including Government, pathologists, healthcare professionals, consumers and suppliers of genomic technologies.

This whitepaper was produced by HTANALYSTS, with broad stakeholder input to identify current HTA challenges and potential solutions for genomic technologies such as large panel tests.

The whitepaper outlines how the HTA review could address many challenges such as the length and efficiency of the Medical Services Advisory Committee (MSAC) HTA process, and improve transparency around evidentiary requirements, value definition and transparency.  It says the reform process could also address larger issues such as funding models and broader legislation.